Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Other Non-Current Assets (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Other Non-Current Assets for 8 consecutive years, with $346111.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 16.8% to $346111.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $346111.0 through Dec 2025, down 16.8% year-over-year, with the annual reading at $417523.0 for FY2025, N/A changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $346111.0 at Outlook Therapeutics, down from $417523.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $464388.0 in Q2 2025, with the low at $346111.0 in Q4 2025.